Published online Jul 16, 2023. doi: 10.12998/wjcc.v11.i20.4763
Peer-review started: January 4, 2023
First decision: April 3, 2023
Revised: April 11, 2023
Accepted: June 6, 2023
Article in press: June 6, 2023
Published online: July 16, 2023
Processing time: 174 Days and 6.9 Hours
Gastric cancer (GC) is one of the most common malignant tumors, and its pathogenesis and biomarkers are still unclear.
The present study for the first time investigated the 10 Hub genes as the potential biomarkers of the prognosis of patients using bioinformatics.
The aims of this study are to explore the potential biomarkers of the prognosis of patients with GC, so as to provide new strategies for the treatment of GC.
In this study, bioinformatics strategy was used to obtain Datasets from The Cancer Genome Atlas, Gene Expression Omnibus and Gene Expression Profiling Interactive Analysis. The software of R software, STRING, Kaplan-Meier plotter and Human Protein Atlas, were performed to analyze and integrate the mRNA datasets, respectively.
The signal pathways of the involvement of the co-expression of differential genes in GC were screened out, and the 10 Hub genes, including BGN, CEP55, COL1A2, COL4A1, FZD2, MAOA, PDGFRB, SPARC, TIMP1 and VCAN, were associated with prognosis of GC and identified as the potential prognostic biomarkers of GC.
The 10 key genes obtained through the analysis of multiple datasets may be used as objective and reliable biomarkers for the survival analysis of patients. In addition, these genes or their encoded proteins can also be as potential therapeutic targets for GC, improving the survival time of patients with GC.
The mechanisms of 10 Hub genes in GC is still unclear, which needs further confirmation through molecular biology and clinical experiments.